Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia

Abstract

Objective

To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.

Methods

This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up. Data on patient demographics, treatment history, laboratory parameters, CAR-T-cell characteristics, safety, and efficacy endpoints were collected. CRS severity was graded according to the 2019 ASTCT consensus criteria. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with CRS severity, and a prognostic model was constructed.

Results

The overall incidence of CRS was 67.2%, with 13.6% having grade ≥ 3 (severe) CRS. Higher baseline and post-lymphodepletion minimal residual disease (MRD) levels and neutropenia on day 7 post-infusion were significantly associated with severe CRS. Inflammatory markers (CRP, ferritin, and IL-6) and coagulation dysfunction (APTT) on day 7 post-infusion were also predictive of CRS severity. The prognostic model incorporating these factors demonstrated robust discriminatory ability, with an area under the ROC curve of 0.875.

Conclusion

This study developed a novel prognostic scoring system for severe CRS in Chinese B-ALL patients receiving anti-CD19 CAR-T-cell therapy. The model integrates clinical and laboratory parameters to facilitate early identification and management of severe CRS. Further validation in larger, prospective cohorts is warranted.

Keywords

Chimeric antigen receptor T-cell immunotherapy / B-cell acute lymphoblastic leukemia / Cytokine release syndrome / Predictive model

References

[1] Maude SL, Laetsch TW, Buechner J, et al.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med, 2018, 378(5): 439-448

[2] Mueller KT, Maude SL, Porter DL, et al.. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017, 130(21): 2317-2325

[3] Wang Y, Lv L, Song Y, et al.. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv, 2025, 9(4): 836-843

[4] Morris EC, Neelapu SS, Giavridis T, et al.. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol, 2022, 22(2): 85-96

[5] Hay K, Hanafi L, Li D, et al.. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood, 2017, 130(21): 2295-2306

[6] Lin JK, Lerman BJ, Barnes JI, et al.. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol, 2018, 36(32): 3192-3202

[7] Bachy E, Le Gouill S, Di Blasi R, et al.. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B-cell lymphoma. Nat Med, 2022, 28(10): 2145-2154

[8] Hansen DK, Sidana S, Peres LC, et al.. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: Real-world experience from the Myeloma CAR T Consortium. J Clin Oncol, 2023, 41(11): 2087-2097

[9] Faramand R, Jain M, Staedtke V, et al.. Tumor microenvironment composition and severe cytokine release syndrome influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res, 2020, 26(18): 4823-4831

[10] Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med, 2020, 383(23): 2255-2273

[11] Granot-Hershkovitz E, He S, Bressler J, et al.. Plasma metabolites associated with cognitive function across race/ethnicities affirming the importance of healthy nutrition. Alzheimers Dement, 2023, 19(4): 1331-1342

[12] Faruqi AJ, Ligon JA, Borgman P, et al.. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Adv, 2022, 6(23): 6040-6050

[13] Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant, 2019, 25(4): 625-638

[14] Zhang M, Long X, Xiao Y, et al.. Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and cytokine release syndrome. J Immunother Cancer, 2023, 11(11 e007790

[15] Pabst T, Joncourt R, Shumilov E, et al.. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Exp Hematol, 2020, 88: 7-14.e13

[16] Ma Y, Zhou H, Zhang J, et al.. The influence of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia. Front Immunol, 2024, 15: 1448709

[17] Yoo JW. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor T-cell therapy. Blood Res, 2023, 58(S1S20-S28

[18] Kopmar NE, Cassaday RD. Clinical insights on brexucabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Cancer Manag Res, 2024, 16: 1587-1596

[19] Greenbaum U, Mahadeo KM, Kebriaei P, et al.. Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: State of the art and future directions. Front Oncol, 2020, 10: 1594

[20] Jiang H, Liu L, Guo T, et al.. Improving the safety of CAR-T cell therapy by controlling cytokine release syndrome-related coagulopathy. Ann Hematol, 2019, 98(71721-1732

[21] Liu D, Zhao J. Cytokine release syndrome: Grading, modeling, and new therapy. J Hematol Oncol, 2018, 11(1121

Funding

National Natural Science Foundation of China(82400212)

RIGHTS & PERMISSIONS

The Author(s)